The liver cancer drugs market size was worth USD 2.67 billion in 2023 is expected to grow to USD 9.94 billion by 2032, rising with a CAGR of 14.2% from 2024 to 2032.

2023年肝癌药物市场规模为26.7亿美元，预计到2032年将增长至99.4亿美元，2024年至2032年的复合年增长率为14.2%。

Discover which segments dominates more in liver cancer drugs market in detail @ https://www.towardshealthcare.com/personalized-scope/5146

详细了解哪些细分市场在肝癌药物市场中占主导地位@https://www.towardshealthcare.com/personalized-scope/5146

Liver cancer, responsible for over 800,000 deaths annually, ranks as the fourth leading cause of death worldwide.

肝癌每年造成80多万人死亡，是全球第四大死亡原因。

Public health authorities are deeply concerned about liver cancer due to its increasing incidence and the low 30%–35% projected 5-year survival rate after diagnosis. Primary liver cancer occurs when malignant cells form in the liver tissues. It's important to distinguish primary liver cancer from metastatic cancer, which originates elsewhere in the body and spreads to the liver..

由于肝癌的发病率不断上升，并且诊断后预计的5年生存率较低，因此公共卫生部门对肝癌深表担忧。当肝组织中形成恶性细胞时，就会发生原发性肝癌。区分原发性肝癌和转移性肝癌很重要，转移性肝癌起源于身体其他部位并扩散到肝脏。。

Hepatocellular carcinoma accounts for approximately 90% of liver cancer cases, with other types like hepatoblastoma and intrahepatic carcinoma being less common. While the exact cause of liver cancer is unknown, chronic hepatitis infections, particularly hepatitis B and hepatitis C, are significant risk factors..

肝细胞癌约占肝癌病例的90%，其他类型如肝母细胞瘤和肝内癌较少见。虽然肝癌的确切原因尚不清楚，但慢性肝炎感染，特别是乙型肝炎和丙型肝炎，是重要的危险因素。。

For example, in 2019, the WHO estimated that there were 296 million individuals worldwide living with chronic hepatitis B infection, with 1.5 million new cases occurring annually. Hepatitis B is responsible for around 820,000 deaths globally, mainly due to hepatocellular carcinoma and liver cirrhosis, both forms of primary liver cancer..

例如，2019年，世界卫生组织估计全世界有2.96亿人患有慢性乙型肝炎感染，每年有150万新病例发生。乙型肝炎导致全球约820000人死亡，主要是由于肝细胞癌和肝硬化，这两种形式的原发性肝癌。。

The primary treatment for advanced liver cancer includes various medications and immunotherapy, while second-line treatments consist of chemotherapeutic medications derived from natural and synthetic sources. First-line treatments such as sorafenib and lenvatinib are used, while regorafenib and ramucirumab are among the second-line options.

晚期肝癌的主要治疗方法包括各种药物和免疫治疗，而二线治疗包括来自天然和合成来源的化疗药物。使用索拉非尼和lenvatinib等一线治疗，而瑞格非尼和雷莫昔单抗是二线选择。

Treatment selection depends largely on the stage of the disease. Tyrosine kinase inhibitors (TKIs), along with other second-line treatments, have shown to prolong survival and improve outcomes in a large population of patients, including those who have undergone immunotherapy, with a stable safety profile..

治疗选择在很大程度上取决于疾病的阶段。酪氨酸激酶抑制剂（TKIs）以及其他二线治疗已显示可延长大量患者（包括接受过免疫治疗的患者）的生存期并改善预后，且安全性稳定。。

Surgical options for liver cancer include hepatectomy, liver transplantation, as well as ablation and radiation therapy.

肝癌的手术选择包括肝切除术，肝移植以及消融和放射治疗。

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

您可以下订单或询问任何问题，请随时联系我们sales@towardshealthcare.com

CSIR's Latest Research Highlights on Liver Cancer Prevention, January 2024

CSIR关于肝癌预防的最新研究重点，2024年1月

In January 2024, the Central Drug Research Institute (CDRI) in India, in collaboration with CIMAP, CBMR, and CSIR-CDRI, released new findings suggesting that preventing liver cancer may involve targeting metabolic changes in cells.

2024年1月，印度中央药物研究所（CDRI）与CIMAP，CBMR和CSIR-CDRI合作，发布了新发现，表明预防肝癌可能涉及靶向细胞代谢变化。

The study, led by Dr. Madhav Nilakanth Mugale of CSIR-CDRI, focused on hepatocellular carcinoma (HCC), the most common form of liver cancer. It revealed that cancer cells undergo metabolic reprogramming, which could be utilized for both preventive and diagnostic purposes.

这项由CSIR-CDRI的MadhavNilakanthMugale博士领导的研究集中于肝细胞癌（HCC），这是最常见的肝癌形式。它揭示了癌细胞经历代谢重编程，这可以用于预防和诊断目的。

Using an animal model to mimic human HCC development, the study observed specific alterations associated with HCC progression, including decreased body mass, elevated serum enzyme levels, and changes in hepatic architecture.

使用动物模型模拟人类HCC的发展，该研究观察到与HCC进展相关的特定改变，包括体重减轻，血清酶水平升高和肝脏结构改变。

Published in the prestigious international journal Elsevier, this research opens avenues for the development of targeted therapies based on metabolic reprogramming.

这项研究发表在著名的国际期刊Elsevier上，为基于代谢重编程的靶向治疗的发展开辟了途径。

Link Between Type 2 Diabetes, Liver Cancer, and Screening Implications

2型糖尿病、肝癌与筛查的关系

Excess fat production in individuals with type 2 diabetes results from the liver's inability to consistently regulate high blood sugar levels. This increases the likelihood of liver cancer, particularly in those with nonalcoholic fatty liver disease (NAFLD).

2型糖尿病患者脂肪过多的原因是肝脏无法持续调节高血糖水平。这增加了肝癌的可能性，特别是那些患有非酒精性脂肪肝（NAFLD）的患者。

NAFLD can lead to irreversible liver inflammation and scarring, ultimately causing cirrhosis. Type 2 diabetes exacerbates liver damage, significantly elevating the risk of liver cancer, which is two to four times higher in diabetic individuals compared to non-diabetic individuals.

NAFLD可导致不可逆的肝脏炎症和瘢痕形成，最终导致肝硬化。2型糖尿病加剧了肝脏损伤，显着提高了肝癌的风险，与非糖尿病患者相比，糖尿病患者的肝癌风险高出2至4倍。

A recent Stanford Medicine study, published in February 2024, suggests that a readily measurable biophysical characteristic can identify type 2 diabetics who are at increased risk of liver cancer but may not meet existing screening criteria.

斯坦福大学医学院（Stanford Medicine）最近于2024年2月发表的一项研究表明，易于测量的生物物理特征可以识别出2型糖尿病患者，这些患者的肝癌风险增加，但可能不符合现有的筛查标准。

Customize this study as per your requirement @  https://www.towardshealthcare.com/customization/5146

根据您的要求定制此研究@https://www.towardshealthcare.com/customization/5146

Implications of the Study:

研究的意义：

Current screening standards primarily target individuals with cirrhosis. However, many high-risk individuals, especially those with type 2 diabetes who may not develop cirrhosis, are overlooked.

目前的筛查标准主要针对肝硬化患者。然而，许多高危人群，尤其是那些可能不会发展为肝硬化的2型糖尿病患者，被忽视了。

The research highlights the necessity of reevaluating screening procedures to include patients with diabetes. Early detection through expanded screening could lead to better outcomes.

该研究强调了重新评估筛查程序以纳入糖尿病患者的必要性。通过扩大筛查进行早期发现可能会导致更好的结果。

This research not only impacts liver cancer screening but may also influence screening strategies for other diabetes-related cancers, such as breast cancer.

这项研究不仅影响肝癌筛查，还可能影响其他糖尿病相关癌症（如乳腺癌）的筛查策略。

Advancements in Liver Cancer Therapy

肝癌治疗进展

In recent years, significant strides have been made by major players in cancer therapeutics in studying and developing new treatment approaches for liver cancers. Manufacturers are actively conducting clinical trials on combination therapies and advancing treatment options.

近年来，癌症治疗领域的主要参与者在研究和开发肝癌的新治疗方法方面取得了重大进展。制造商正在积极进行联合疗法的临床试验，并推进治疗方案。

For instance:

例如：

Terumo Introduces B-TACE (Balloon-TACE) Therapy

Terumo推出B-TACE（球囊TACE）治疗

In March 2024, Japan-based company Terumo launched B-TACE (Balloon-TACE), an advanced therapy for managing liver cancer. Terumo's B-TACE device, Occlusafe, allows chemotherapy drugs to be delivered to the tumor with greater precision and targeting. This results in less harm to surrounding healthy tissues..

2024年3月，总部位于日本的Terumo公司推出了B-TACE（气球TACE），这是一种治疗肝癌的先进疗法。Terumo的B-TACE设备Occlusafe允许化疗药物以更高的精确度和靶向性递送至肿瘤。这对周围健康组织的危害较小。。

Biosyngen’s BST02 Receives Fast Track Designation

Biosyngen的BST02获得快速通道指定

In February 2024, Biosyngen’s BST02 received a Fast Track Designation (FTD) grant from the US FDA covering the management of all forms of liver cancer, including cholangiocarcinoma and hepatocellular carcinoma.

2024年2月，Biosyngen的BST02获得了美国FDA的快速通道指定（FTD）拨款，涵盖所有形式的肝癌的管理，包括胆管癌和肝细胞癌。

AstraZeneca’s EMERALD-1 Trial Shows Positive Results

阿斯利康的EMERALD-1试验显示了积极的结果

In January 2024, AstraZeneca’s EMERALD-1 Phase III trial yielded positive results. Patients with hepatocellular carcinoma (HCC) eligible for embolization saw a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) when Imfinzi (durvalumab) was combined with TACE and bevacizumab, compared to TACE alone..

2024年1月，阿斯利康的EMERALD-1 III期试验取得了积极成果。与单独的TACE相比，当Imfinzi（durvalumab）与TACE和贝伐单抗联合使用时，符合栓塞条件的肝细胞癌（HCC）患者的无进展生存期（PFS）主要终点有统计学意义和临床意义的改善。。

Terumo Introduces B-TACE (Balloon-TACE) Therapy

Terumo推出B-TACE（球囊TACE）治疗

In November 2023, Japan-based company Terumo launched B-TACE (Balloon-TACE), an advanced therapy for managing liver cancer. Terumo's B-TACE device, Occlusafe, allows chemotherapy drugs to be delivered to the tumor with greater precision and targeting, resulting in less harm to surrounding healthy tissues..

2023年11月，总部位于日本的Terumo公司推出了B-TACE（气球TACE），这是一种治疗肝癌的先进疗法。Terumo的B-TACE设备Occlusafe可以更精确和更有针对性地将化疗药物输送到肿瘤中，从而减少对周围健康组织的伤害。。

Evolution of Liver Cancer Therapy Landscape

肝癌治疗景观的演变

Over the past 16 years, the treatment landscape of hepatocellular carcinoma has exhibited a significant transformation due to major advancements in targeted therapy. This growing journey can be attributed to several factors such as:

在过去的16年中，由于靶向治疗取得了重大进展，肝细胞癌的治疗前景发生了重大转变。这一成长历程可归因于以下几个因素：

Sorafenib (2007): Sorafenib being the first ever effective and approved targeted therapy for advanced HCC, marked a turning point in liver cancer therapeutics. This innovation opened new doors to more therapeutic developments.

索拉非尼（2007）：索拉非尼是有史以来第一种有效且经批准的晚期HCC靶向治疗，标志着肝癌治疗的转折点。这一创新为更多的治疗发展打开了新的大门。

Emerging Treatment Options: New targeted medicines such as Lenvatinib and the combination of Bevacizumab and Atezolizumab have become viable first-line therapeutic choices for patients with advanced HCC, capitalizing on the therapeutic efficacy of Sorafenib. The introduction of Ramucirumab, Regorafenib, and Cabozantinib (for patients with AFP > 400 ng/mL) has greatly expanded the therapeutic choices available for advanced HCC patients receiving second-line treatment..

新兴的治疗选择：新的靶向药物如Lenvatinib以及贝伐单抗和Atezolizumab的组合已成为晚期HCC患者可行的一线治疗选择，利用索拉非尼的治疗效果。雷莫西鲁单抗，瑞格非尼和卡博替尼（AFP>400 ng/mL的患者）的引入极大地扩大了接受二线治疗的晚期HCC患者的治疗选择。。

Sr. No.

高级职员编号。

Type of Therapy

治疗类型

Targeted Therapies

靶向治疗

1.

1.

Tyrosine Kinase Inhibitors

酪氨酸激酶抑制剂

Sorafenib

索拉非尼

Lenvatinib

乐伐替尼

Cabozantinib

卡博扎替尼

Regorafenib

瑞戈非尼

2.

2.

VEGF Inhibitors

VEGF抑制剂

Bevacizumab + Atezolizumab

贝伐单抗+阿替佐利单抗

Ramucirumab

Ramucirumab

3.

3.

Other Targeted Agents

其他目标代理商

Donafenib

多纳非尼

Nintedanib

Nintedanib

Galunisertib

Galunisertib

Galunisertib + Sorafenib

Galunisertib+索拉非尼

Patients with advanced HCC can now expect better treatment outcomes and a more optimistic prognosis because of these developments in targeted therapy.

由于靶向治疗的这些发展，晚期HCC患者现在可以期望更好的治疗结果和更乐观的预后。

BST02's Fast Track Designation Grant: A Recent Breakthrough in Liver Cancer Treatment

BST02的快速通道指定拨款：肝癌治疗的最新突破

Biosyngen's immune therapy product, BST02, received the FDA's Fast Track Development Grant in February 2024 for its clinical development to treat all types of liver cancer. Biosyngen, an immune-oncology company, is pioneering cancer treatment development and approval by leveraging the patient's immune system to combat cancer—a strategy that may outperform more established TIL medicines.

Biosyngen的免疫治疗产品BST02于2024年2月获得了FDA的快速发展资助，用于治疗所有类型的肝癌。免疫肿瘤学公司Biosyngen通过利用患者的免疫系统对抗癌症，开创了癌症治疗开发和批准的先河，这一策略可能优于更成熟的TIL药物。

BST02 is an adoptive immune cell treatment, a T cell therapy based on the patient's own tumor infiltrating lymphocytes, which are expanded in vitro. It holds promise in treating liver cancer in all its forms, offering renewed hope for sufferers. Compared to conventional TIL therapies, BST02 boasts several advantages, including its cryopreserved form, which allows it to overcome geographic limitations, and reduced reliance on large interleukin-2 dosages..

BST02是一种过继性免疫细胞疗法，是一种基于患者自身肿瘤浸润淋巴细胞的T细胞疗法，可在体外扩增。它有望治疗各种形式的肝癌，为患者带来新的希望。与传统的TIL疗法相比，BST02具有几个优点，包括其冷冻保存形式，它可以克服地理限制，并减少对大剂量白细胞介素-2的依赖。。

Geographical Disparities in Liver Cancer Incidence

肝癌发病率的地理差异

Despite significant progress in prevention and control, the incidence and prevalence of non-infectious diseases have surged in recent decades.

尽管在预防和控制方面取得了重大进展，但近几十年来非传染性疾病的发病率和流行率急剧上升。

Liver cancer ranks second in cancer-related deaths and is the sixth most common cancer globally. In Asia alone, approximately 609,596 new cases of liver cancer were reported in 2020, accounting for about 72.5% of global liver cancer incidence.

肝癌在癌症相关死亡中排名第二，是全球第六大常见癌症。仅在亚洲，2020年就报告了约609596例新发肝癌病例，约占全球肝癌发病率的72.5%。

Regional variations exist; sub-Saharan Africa and East Asia have the highest rates, though their underlying causes differ. High-income countries have witnessed a decline in liver cancer cases due to widespread viral hepatitis treatment and vaccination programs. Conversely, there is an increase in low-income countries, often linked to unsafe injection practices and viral hepatitis..

存在区域差异；撒哈拉以南非洲和东亚的发病率最高，尽管其根本原因各不相同。由于广泛的病毒性肝炎治疗和疫苗接种计划，高收入国家的肝癌病例有所下降。相反，低收入国家有所增加，通常与不安全的注射做法和病毒性肝炎有关。。

Browse More Insights of Towards Healthcare:

浏览更多有关医疗保健的见解：

Spinal Cord Injury Treatment Market Size Report 2023 – 2032

2023-2032年脊髓损伤治疗市场规模报告

Musculoskeletal Disorders Treatment Market Size Report 2023 – 2032

2023-2032年肌肉骨骼疾病治疗市场规模报告

Non-Steroidal Anti-Inflammatory Drugs Market Size Report 2023 – 2032

2023-2032年非甾体类抗炎药市场规模报告

Nanomedicine Market Size Report 2023 - 2032

2023-2032年纳米医学市场规模报告

Vein Finder Market Size Report 2023 – 2032

2023-2032年静脉探测仪市场规模报告

Hemato Oncology Testing Market Size Report 2023 – 2033

2023-2033年血液肿瘤检测市场规模报告

AI In MRI Market Size Report 2023 – 2032

2023-2032年MRI市场规模报告中的AI

Blockchain in Healthcare Market Size Report 2023 - 2032

区块链在医疗保健市场规模报告2023-2032

AI In Life Sciences Market Size Report 2023 – 2032

人工智能在生命科学领域的市场规模报告2023-2032

AI in Drug Discovery Market Size Report 2023 - 2032

2023-2032年药物发现市场规模报告中的AI

Liver Cancer Drugs Market Players

肝癌药物市场参与者

Bayer AG

拜耳公司

Bristol-Myers Squibb Company

百时美施贵宝公司

Eisai Co., Ltd.

Eisai有限公司

Exelixis, Inc.

股份有限公司Exelixis。

Merck KGaA

默克集团

Pfizer Inc.

辉瑞公司。

Eisai Inc.

Eisai股份有限公司。

Eli Lilly and Company

礼来公司

F. Hoffmann-La Roche Ltd.

F、 霍夫曼·拉罗氏有限公司。

Liver Cancer Drugs Market Segments

肝癌药物市场细分

By Drug Class

按药物类别

Targeted Therapy

靶向治疗

Bevacizumab

贝伐单抗

Cabozantinib

卡博扎替尼

Lenvatinib

乐伐替尼

Ramucirumab

Ramucirumab

Regorafenib

瑞戈非尼

Sorafenib

索拉非尼

Other Targeted Therapies

其他靶向治疗

Immunotherapy

免疫疗法

Atezolizumab with Bevacizumab

阿替佐利珠单抗与贝伐单抗

Nivolumab with Ipilimumab

Nivolumab与Ipilimumab

Pembrolizumab

Pembrolizumab

Durvalumab with Tremelimumab

Durvalumab与Tremelimumab

Other Immunotherapies

其他免疫疗法

Chemotherapy

化疗

Gemcitabine

吉西他滨

Oxaliplatin

奥沙利铂

Cisplatin

顺铂

Doxorubicin

阿霉素

5-fluorouracil

5-氟尿嘧啶

Capecitabine

卡培他滨

Mitoxantrone

米托蒽醌

Other Chemotherapies

其他化学疗法

By Distribution Channel

按分销渠道

Hospital Pharmacy

医院药房

Retail Pharmacy

零售药房

Online Pharmacy

网上药房

By Geography

按地理位置

North America

北美

Europe

欧洲

Asia Pacific

亚太地区

Middle East and Africa

中东和非洲

South America

南美洲

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5146

立即获取我们的综合分析@https://www.towardshealthcare.com/price/5146

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

您可以下订单或询问任何问题，请随时联系我们sales@towardshealthcare.com

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations.

通过订阅我们的年度会员资格，获得医疗保健行业的最新见解和统计数据。通过根据您的需求量身定制的详细报告、市场趋势和专家分析，随时了解医疗保健行业细分情况。凭借宝贵的资源和战略建议保持领先。

Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription.

立即加入，在充满活力的医疗保健世界中开启丰富的知识和机会：订阅。

About Us

关于我们

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth.

迈向医疗保健是全球领先的医疗保健领域技术解决方案、临床研究服务和高级分析服务提供商，致力于形成创造性联系，从而产生可行的见解和创造性创新。我们是一家全球战略咨询公司，帮助企业领导者获得竞争优势并加速增长。

We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations..

我们为医疗保健行业提供技术解决方案、临床研究服务和高级分析，致力于形成创造性联系，从而产生可行的见解和创造性创新。。

Browse our Brand-New Journals:

浏览我们的全新期刊：

https://www.towardspackaging.com

https://www.towardspackaging.com

https://www.towardsautomotive.com

https://www.towardsautomotive.com

Web: https://www.precedenceresearch.com

网状物https://www.precedenceresearch.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

有关最新更新，请联系我们：https://www.linkedin.com/company/towards-healthcare

Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com

获取我们新印刷的历史记录：https://www.healthcarewebwire.com